Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: LPN002
MIFTS: 41

Lip and Oral Cavity Cancer

Categories: Cancer diseases, Oral diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Lip and Oral Cavity Cancer

About this section

MalaCards integrated aliases for Lip and Oral Cavity Cancer:

Name: Lip and Oral Cavity Cancer 20
Lip and Oral Cavity Carcinoma 6

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Oral diseases
See all MalaCards categories (disease lists)


Sources

Summaries for Lip and Oral Cavity Cancer

About this section
MalaCards based summary : Lip and Oral Cavity Cancer, also known as lip and oral cavity carcinoma, is related to oral cancer and vulvar intraepithelial neoplasia. An important gene associated with Lip and Oral Cavity Cancer is CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), and among its related pathways/superpathways are Signaling by GPCR and ERK Signaling. The drugs Nicotine and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include liver, and related phenotypes are Decreased viability and Decreased viability

Sources

Related Diseases for Lip and Oral Cavity Cancer

About this section

Diseases related to Lip and Oral Cavity Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 361)
# Related Disease Score Top Affiliating Genes
1 oral cancer 32.2 TP53 EGFR CDKN2A
2 vulvar intraepithelial neoplasia 10.3 TP53 CDKN2A
3 ovarian seromucinous carcinoma 10.3 TP53 CDKN2A
4 human papillomavirus infectious disease 10.3 TP53 CDKN2A
5 b-lymphoblastic leukemia/lymphoma, bcr-abl1-like 10.3 CDKN2A ABL1
6 bizarre leiomyoma 10.3 TP53 CDKN2A
7 localized osteosarcoma 10.3 TP53 CDKN2A
8 chronic cervicitis 10.3 TP53 CDKN2A
9 thyroid lymphoma 10.3 TP53 CDKN2A
10 bladder clear cell adenocarcinoma 10.3 TP53 CDKN2A
11 nevus of ota 10.3 TP53 BRAF
12 trachea carcinoma in situ 10.3 HRAS CDKN2A
13 adult astrocytic tumour 10.3 TP53 CDKN2A
14 bile duct adenoma 10.3 TP53 CDKN2A
15 vaginal cancer 10.3 TP53 CDKN2A
16 low-grade astrocytoma 10.3 TP53 CDKN2A
17 cervical adenoid cystic carcinoma 10.2 KIT CDKN2A
18 laryngeal small cell carcinoma 10.2 KIT CDKN2A
19 borst-jadassohn intraepidermal carcinoma 10.2 TP53 CDKN2A
20 maxillary sinus benign neoplasm 10.2 KIT CDKN2A
21 neurofibrosarcoma 10.2 TP53 CDKN2A
22 vulvar dystrophy 10.2 TP53 CDKN2A
23 oral cavity cancer 10.2
24 biliary tract benign neoplasm 10.2 TP53 HRAS
25 megaesophagus 10.2 TP53 CDKN2A
26 lip cancer 10.2 TP53 BRAF
27 intratubular embryonal carcinoma 10.2 TP53 KIT
28 appendix disease 10.2 TP53 HRAS
29 papillary adenoma 10.2 TP53 HRAS
30 appendix cancer 10.2 TP53 HRAS
31 malignant peritoneal mesothelioma 10.2 EGFR CDKN2A
32 glomangiomatosis 10.2 TP53 KIT
33 ovarian benign neoplasm 10.2 TP53 HRAS
34 myeloid and lymphoid neoplasms associated with pdgfra rearrangement 10.2 KIT ABL1
35 papillary squamous carcinoma 10.2 EGFR CDKN2A
36 embryonal sarcoma 10.2 TP53 KIT
37 conventional fibrosarcoma 10.2 TP53 KIT
38 esophageal basaloid squamous cell carcinoma 10.2 TP53 EGFR
39 pectus excavatum 10.2 TP53 ABL1
40 frontal lobe neoplasm 10.2 TP53 EGFR
41 tenosynovial giant cell tumor 10.2 KIT CDKN2A
42 adenofibroma 10.2 TP53 BRAF
43 malignant anus melanoma 10.2 KIT HRAS
44 spinal cord oligodendroglioma 10.2 TP53 EGFR
45 malignant dermis tumor 10.2 KIT HRAS
46 malignant skin fibrous histiocytoma 10.2 KIT HRAS
47 soft tissue sarcoma 10.2 TP53 EGFR
48 parameningeal embryonal rhabdomyosarcoma 10.2 TP53 PIK3CA
49 mammary analogue secretory carcinoma 10.2 TP53 EGFR
50 urinary bladder inverted papilloma 10.2 RB1 CDKN2A

Graphical network of the top 20 diseases related to Lip and Oral Cavity Cancer:



Diseases related to Lip and Oral Cavity Cancer
Sources

Symptoms & Phenotypes for Lip and Oral Cavity Cancer

About this section

GenomeRNAi Phenotypes related to Lip and Oral Cavity Cancer according to GeneCards Suite gene sharing:

26 (show all 50)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.67 BRAF EGFR PIK3CA HRAS
2 Decreased viability GR00055-A-2 10.67 BRAF EGFR PIK3CA HRAS
3 Decreased viability GR00221-A-1 10.67 CDKN2A EGFR PIK3CA HRAS ABL1 KIT
4 Decreased viability GR00221-A-2 10.67 PIK3CA HRAS ABL1
5 Decreased viability GR00221-A-3 10.67 CDKN2A HRAS ABL1
6 Decreased viability GR00221-A-4 10.67 BRAF CDKN2A EGFR PIK3CA
7 Decreased viability GR00249-S 10.67 BRAF
8 Decreased viability GR00301-A 10.67 BRAF KIT
9 Decreased viability GR00342-S-1 10.67 ABL1
10 Decreased viability GR00342-S-2 10.67 ABL1
11 Decreased viability GR00342-S-3 10.67 ABL1
12 Decreased viability GR00381-A-1 10.67 BRAF
13 Decreased viability GR00402-S-2 10.67 PIK3CA
14 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.27 EGFR
15 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.27 ABL1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.27 KIT
17 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.27 ABL1 KIT
18 Increased shRNA abundance (Z-score > 2) GR00366-A-170 10.27 KIT
19 Increased shRNA abundance (Z-score > 2) GR00366-A-172 10.27 RB1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.27 RB1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-181 10.27 RB1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-196 10.27 HRAS
23 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.27 EGFR
24 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.27 RB1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-213 10.27 ABL1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.27 EGFR
27 Increased shRNA abundance (Z-score > 2) GR00366-A-28 10.27 HRAS
28 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10.27 ABL1 KIT
29 Increased shRNA abundance (Z-score > 2) GR00366-A-34 10.27 ABL1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.27 ABL1 EGFR RB1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.27 ABL1
32 Increased shRNA abundance (Z-score > 2) GR00366-A-50 10.27 RB1
33 Increased shRNA abundance (Z-score > 2) GR00366-A-60 10.27 PIK3CA
34 Increased shRNA abundance (Z-score > 2) GR00366-A-61 10.27 KIT
35 Increased shRNA abundance (Z-score > 2) GR00366-A-83 10.27 HRAS
36 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.27 ABL1 EGFR KIT
37 Increased shRNA abundance (Z-score > 2) GR00366-A-87 10.27 HRAS
38 Increased shRNA abundance (Z-score > 2) GR00366-A-9 10.27 KIT
39 Increased shRNA abundance (Z-score > 2) GR00366-A-91 10.27 EGFR
40 Increased shRNA abundance (Z-score > 2) GR00366-A-99 10.27 KIT
41 Decreased substrate adherent cell growth GR00193-A-1 10.07 KIT
42 Decreased substrate adherent cell growth GR00193-A-2 10.07 ABL1 EGFR KIT
43 Decreased substrate adherent cell growth GR00193-A-3 10.07 BRAF
44 Decreased substrate adherent cell growth GR00193-A-4 10.07 ABL1 KIT BRAF
45 Decreased cell migration GR00055-A-1 10.02 ABL1
46 Decreased cell migration GR00055-A-3 10.02 BRAF EGFR HRAS PIK3CA
47 Decreased Hepatitis C Virus pseudoparticles (HCVpp; H77; genotype 1a) infection GR00234-A-1 9.5 BRAF EGFR STK11
48 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-1 9.28 TP53
49 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-2 9.28 ABL1 BRAF CDKN2A RB1 TP53
50 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.28 ABL1 BRAF TP53

MGI Mouse Phenotypes related to Lip and Oral Cavity Cancer:

46 (show all 26)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.32 ABL1 BRAF CDKN2A EGFR HRAS KIT
2 endocrine/exocrine gland MP:0005379 10.29 ABL1 BRAF CDKN2A EGFR HRAS KIT
3 behavior/neurological MP:0005386 10.28 ABL1 BRAF CDKN2A HRAS KIT PIK3CA
4 growth/size/body region MP:0005378 10.28 ABL1 BRAF CDKN2A EGFR HRAS KIT
5 cellular MP:0005384 10.27 ABL1 BRAF CDKN2A EGFR KIT PIK3CA
6 digestive/alimentary MP:0005381 10.26 ABL1 BRAF CDKN2A EGFR HRAS KIT
7 homeostasis/metabolism MP:0005376 10.26 ABL1 BRAF CDKN2A EGFR HRAS KIT
8 embryo MP:0005380 10.25 ABL1 BRAF CDKN2A EGFR KIT PIK3CA
9 craniofacial MP:0005382 10.21 ABL1 BRAF EGFR HRAS KIT RB1
10 mortality/aging MP:0010768 10.21 ABL1 BRAF CDKN2A EGFR HRAS KIT
11 immune system MP:0005387 10.2 ABL1 BRAF CDKN2A EGFR KIT PIK3CA
12 integument MP:0010771 10.19 BRAF CDKN2A EGFR HRAS KIT PIK3CA
13 muscle MP:0005369 10.19 ABL1 BRAF CDKN2A EGFR HRAS KIT
14 hematopoietic system MP:0005397 10.17 ABL1 BRAF CDKN2A EGFR KIT RB1
15 nervous system MP:0003631 10.16 ABL1 BRAF CDKN2A EGFR HRAS KIT
16 liver/biliary system MP:0005370 10.13 ABL1 BRAF CDKN2A EGFR KIT RB1
17 neoplasm MP:0002006 10.13 BRAF CDKN2A EGFR HRAS KIT PIK3CA
18 no phenotypic analysis MP:0003012 10.03 CDKN2A EGFR HRAS KIT PIK3CA RB1
19 normal MP:0002873 10.01 ABL1 BRAF EGFR HRAS KIT RB1
20 hearing/vestibular/ear MP:0005377 9.97 BRAF EGFR KIT RB1 TP53
21 renal/urinary system MP:0005367 9.87 BRAF EGFR HRAS KIT RB1 STK11
22 reproductive system MP:0005389 9.86 BRAF CDKN2A EGFR KIT PIK3CA RB1
23 pigmentation MP:0001186 9.85 BRAF CDKN2A EGFR KIT RB1 TP53
24 respiratory system MP:0005388 9.81 ABL1 BRAF CDKN2A EGFR HRAS KIT
25 skeleton MP:0005390 9.61 ABL1 BRAF CDKN2A EGFR HRAS KIT
26 vision/eye MP:0005391 9.28 ABL1 BRAF CDKN2A EGFR KIT PIK3CA
Sources

Drugs & Therapeutics for Lip and Oral Cavity Cancer

About this section

Drugs for Lip and Oral Cavity Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 39)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nicotine Approved Phase 4 54-11-5 942 89594
2
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
3
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
4 Liver Extracts Phase 4
5 Central Nervous System Stimulants Phase 4
6 Neurotransmitter Agents Phase 4
7 Nicotinic Agonists Phase 4
8 Cholinergic Agents Phase 4
9 Dopamine Agents Phase 4
10 Cytochrome P-450 Enzyme Inhibitors Phase 4
11 Dopamine Uptake Inhibitors Phase 4
12 Antidepressive Agents Phase 4
13 Psychotropic Drugs Phase 4
14
Pilocarpine Approved, Investigational Phase 2, Phase 3 92-13-7, 54-71-7 5910
15 Muscarinic Agonists Phase 2, Phase 3
16
Zinc oxide Approved Phase 2 1314-13-2
17
Zinc Approved, Investigational Phase 2 7440-66-6 32051
18
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
19
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
20
Fenretinide Investigational Phase 2 65646-68-6
21 Radiation-Protective Agents Phase 2
22 Dermatologic Agents Phase 2
23 Sunscreening Agents Phase 2
24 Zinc Supplement Phase 2
25 Anti-Inflammatory Agents Phase 2
26 Analgesics, Non-Narcotic Phase 2
27 Cyclooxygenase 2 Inhibitors Phase 2
28 Anti-Inflammatory Agents, Non-Steroidal Phase 2
29 Analgesics Phase 2
30 Cyclooxygenase Inhibitors Phase 2
31 Antirheumatic Agents Phase 2
32 Antineoplastic Agents, Immunological Phase 2
33 Protective Agents Phase 2
34 Retinamide Phase 2
35
Ethanol Approved 64-17-5 702
36
Methadone Approved 76-99-3 4095
37
Varenicline Approved, Investigational 249296-44-4 5310966
38 Lemon Balm
39 Fluorides

Interventional clinical trials:

(show all 25)
# Name Status NCT ID Phase Drugs
1 Comparing the Lozenge to the Patch for Smoking Cessation Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
2 Enhancing Tobacco Use Treatment for African American Light Smokers Completed NCT00666978 Phase 4 bupropion hydrochloride
3 A Phase II/III Study Comparing Acupuncture-like Transcutaneous Electrical Nerve Stimulation (ALTENS) Versus Pilocarpine in Treating Early Radiation-Induced Xerostomia Completed NCT00656513 Phase 2, Phase 3 Pilocarpine
4 Do Dietary Supplements of Zinc Reduce Serum Cadmium Levels in Smokers? Completed NCT00376987 Phase 2
5 Phase II Double-Blind, Placebo Controlled, Randomized Study Of Celecoxib, A Selective COX-2 Inhibitor, In Oral Premalignant Lesions Completed NCT00014404 Phase 2 celecoxib
6 Celecoxib In Biomarker Modulation Of Oral Precancerous Lesions: A Pilot Study Completed NCT00052611 Phase 2 Celecoxib
7 A Randomized, Double Blind, Placebo-Controlled Phase II Clinical Trial of N(4-Hydroxy-phenyl)Retinamide (Fenretinide, 4HPR) in Oral Leukoplakia Completed NCT00004161 Phase 2 fenretinide;Placebo
8 A Phase IIb Cancer Prevention Trial of Celecoxib, a Selective COX-2 Inhibitor, in Oral Leukoplakia Completed NCT00101335 Phase 2 celecoxib
9 A Phase II Study of the Effects of Extended Pre-Cessation Bupropion for Smoking Cessation Completed NCT00534001 Phase 2 bupropion hydrochloride
10 Phase II Study of Single-Agent Cetuximab for Treatment of High-Risk Pre-malignant Upper Aerodigestive Lesions Completed NCT00524017 Phase 2
11 Bowman Birk Inhibitor Concentrate and Oral Leukoplakia: A Randomized Phase IIb Trial Completed NCT00330382 Phase 2 Bowman-Birk inhibitor concentrate
12 Clinical Protocol for Wild Type p53 Gene Induction in Premalignancies of Squamous Epithelium of the Oral Cavity and Oral Pharynx Via an Adenoviral Vector [NCI Supplied Agent Ad-p53, (INGN 201) (Advexin®) NSC 683550, IND# 7135] Completed NCT00064103 Phase 1, Phase 2
13 A Single Arm, Phase II Study to Determine the Safety and Efficacy of 4-HPRN-(4-Hydroxyphenyl) Retinamide for Treating Oral Intraepithelial Neoplasia Terminated NCT00003223 Phase 2 fenretinide
14 Phase I Study of Intraarterial ONYX-015 in Combination With Intravenous Cisplatin and Fluorouracil in Patients With Advanced Squamous Cell Cancer of the Head and Neck Withdrawn NCT00006106 Phase 1 cisplatin;fluorouracil;ONYX-015
15 Cancer Risk Reduction Through Combined Treatment for Tobacco and Alcohol Use Unknown status NCT00799669
16 Computerized Scheduling of Nicotine Inhaler Use Completed NCT00021138 nicotine
17 Smoking Relapse Prevention Among Postpartum Women Completed NCT00310115
18 Varenicline Versus Nicotine Replacement for Methadone-Maintained Smokers Completed NCT00790569 nicotine;varenicline
19 Neurocognitive Functioning in Adults With Upper Aerodigestive System Cancers Completed NCT00533884
20 Oral Cancer Screening: Practices, Knowledge and Opinions of Ohio Nursing Home Dentists Completed NCT00526851
21 International Study of the Acceptability of Less Harmful Alternatives to Cigarettes (ISALHAC) - A Pilot Study Completed NCT00957424 nicotine replacement therapy
22 A Phase III Prospective Randomized Trial of Acupuncture for Treatment of Radiation-Induced Xerostomia in Patients With Head and Neck Cancer Recruiting NCT02589938
23 Biomarkers and Dysplastic Respiratory Epithelium Recruiting NCT00900419
24 Measuring Patient Satisfaction With Facial Appearance: Development and Validation of a New Patient-Reported Outcome Measure Active, not recruiting NCT00530049
25 Electroacupuncture for Xerostomia in Head and Neck Patients Terminated NCT00623129

Search NIH Clinical Center for Lip and Oral Cavity Cancer

Sources

Genetic Tests for Lip and Oral Cavity Cancer

About this section
Sources

Anatomical Context for Lip and Oral Cavity Cancer

About this section

MalaCards organs/tissues related to Lip and Oral Cavity Cancer:

40
Liver
Sources

Publications for Lip and Oral Cavity Cancer

About this section

Articles related to Lip and Oral Cavity Cancer:

(show all 13)
# Title Authors PMID Year
1
Oral squamous cell carcinoma resection and neck dissection mortality: a 10-year national audit study. 61
33244898 2021
2
The Inequitable Global Burden of Lip and Oral Cancers: Widening Disparities Across Countries. 61
33497647 2020
3
Oral potentially malignant disorders: A consensus report from an international seminar on nomenclature and classification, convened by the WHO Collaborating Centre for Oral Cancer. 61
33128420 2020
4
The worldwide burden of smoking-related oral cancer deaths. 61
32250564 2020
5
Prevalence and incidence of oral cancer in low- and middle-income countries: A scoping review. 61
31820851 2020
6
Implementation of Early Detection Services for Cancer in India During COVID-19 Pandemic. 61
32938229 2020
7
Increased risk of larynx cancer in patients with gastroesophageal reflux disease from a national sample cohort. 61
30884136 2019
8
Association Between Cancer Incidence and Mortality in Web-Based Data in China: Infodemiology Study. 61
30694203 2019
9
SEOM clinical guidelines for the treatment of head and neck cancer (2017). 61
29159792 2018
10
The Global Burden of Cancer 2013. 61
26181261 2015
11
Factors associated with lip and oral cavity cancer. 61
26247186 2015
12
High-dose-rate brachytherapy using molds for lip and oral cavity tumors. 61
25888772 2015
13
Distant metastases from lip and oral cavity cancer. 61
11408816 2001
Sources

Variations for Lip and Oral Cavity Cancer

About this section

ClinVar genetic disease variations for Lip and Oral Cavity Cancer:

6 (show all 48)
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 RASGRP3 NM_170672.3(RASGRP3):c.-261+9727G>T SNV association 236028 rs2124437 2:33682737-33682737 2:33457670-33457670
2 GRIK2 NM_021956.4(GRIK2):c.2086-16819C>T SNV association 252988 rs1335022 6:102466397-102466397 6:102018522-102018522
3 PREX2 NM_024870.4(PREX2):c.142-2489C>T SNV association 252989 rs4512367 8:68927592-68927592 8:68015357-68015357
4 SNTB1 NM_021021.4(SNTB1):c.571+12964G>A SNV association 430630 rs10090787 8:121810549-121810549 8:120798309-120798309
5 SAMD4A NM_015589.6(SAMD4A):c.1176+4220T>C SNV association 430718 rs1957358 14:55222475-55222475 14:54755757-54755757
6 ANKRD17 NM_032217.5(ANKRD17):c.7731G>A (p.Thr2577=) SNV association 430719 rs2306058 4:73942678-73942678 4:73076961-73076961
7 CNTN4 NM_175607.3(CNTN4):c.55+61947C>T SNV association 430714 rs9849237 3:2675189-2675189 3:2633505-2633505
8 FHIT NM_002012.4(FHIT):c.104-196657C>A SNV association 431027 rs11130760 3:60196537-60196537 3:60210809-60210809
9 LNX1 NM_001126328.3(LNX1):c.381-27505G>A SNV association not found 619293 rs1435218 4:54401899-54401899 4:53535732-53535732
10 CCDC3 NM_031455.4(CCDC3):c.550-478A>G SNV association not found 619294 rs4748011 10:12941157-12941157 10:12899157-12899157
11 MMP2 NM_004530.5(MMP2):c.-1586C>T SNV association 429032 rs243865 16:55511806-55511806 16:55477894-55477894
12 TP53 NM_000546.5(TP53):c.517G>A (p.Val173Met) SNV Pathogenic 233951 rs876660754 17:7578413-7578413 17:7675095-7675095
13 TP53 NM_000546.6(TP53):c.524G>A (p.Arg175His) SNV Pathogenic 12374 rs28934578 17:7578406-7578406 17:7675088-7675088
14 TP53 NM_000546.6(TP53):c.743G>A (p.Arg248Gln) SNV Pathogenic 12356 rs11540652 17:7577538-7577538 17:7674220-7674220
15 TP53 NM_000546.6(TP53):c.638G>A (p.Arg213Gln) SNV Pathogenic 135359 rs587778720 17:7578211-7578211 17:7674893-7674893
16 TP53 NM_000546.6(TP53):c.742C>T (p.Arg248Trp) SNV Pathogenic 12347 rs121912651 17:7577539-7577539 17:7674221-7674221
17 TP53 NM_000546.5(TP53):c.916C>T (p.Arg306Ter) SNV Pathogenic 142144 rs121913344 17:7577022-7577022 17:7673704-7673704
18 HRAS NM_005343.4(HRAS):c.37G>C (p.Gly13Arg) SNV Pathogenic 35554 rs104894228 11:534286-534286 11:534286-534286
19 PIK3CA NM_006218.4(PIK3CA):c.1625A>C (p.Glu542Ala) SNV Pathogenic 376473 rs1057519927 3:178936083-178936083 3:179218295-179218295
20 PIK3CA NM_006218.4(PIK3CA):c.3140A>G (p.His1047Arg) SNV Pathogenic 13652 rs121913279 3:178952085-178952085 3:179234297-179234297
21 PIK3CA NM_006218.4(PIK3CA):c.1624G>A (p.Glu542Lys) SNV Pathogenic 31944 rs121913273 3:178936082-178936082 3:179218294-179218294
22 HRAS NM_005343.4(HRAS):c.38G>T (p.Gly13Val) SNV Pathogenic 180848 rs104894226 11:534285-534285 11:534285-534285
23 HRAS NM_005343.4(HRAS):c.34G>A (p.Gly12Ser) SNV Pathogenic 12602 rs104894229 11:534289-534289 11:534289-534289
24 CDKN2A NM_000077.5(CDKN2A):c.238C>T SNV Pathogenic 9409 rs121913388 9:21971120-21971120 9:21971121-21971121
25 TP53 NM_000546.6(TP53):c.610G>T (p.Glu204Ter) SNV Pathogenic 977783 17:7578239-7578239 17:7674921-7674921
26 CDKN2A NM_000077.5(CDKN2A):c.330G>A SNV Pathogenic 376303 rs121913389 9:21971028-21971028 9:21971029-21971029
27 TP53 NM_000546.5(TP53):c.376-1G>A SNV Pathogenic 481003 rs868137297 17:7578555-7578555 17:7675237-7675237
28 TP53 NM_000546.5(TP53):c.722C>T (p.Ser241Phe) SNV Pathogenic 12359 rs28934573 17:7577559-7577559 17:7674241-7674241
29 TP53 NM_000546.6(TP53):c.731G>C SNV Pathogenic 458560 rs985033810 17:7577550-7577550 17:7674232-7674232
30 TP53 NM_000546.5(TP53):c.799C>T (p.Arg267Trp) SNV Pathogenic 141764 rs55832599 17:7577139-7577139 17:7673821-7673821
31 TP53 NM_000546.6(TP53):c.820G>T SNV Pathogenic 376674 rs1057520005 17:7577118-7577118 17:7673800-7673800
32 TP53 NM_000546.5(TP53):c.821T>G (p.Val274Gly) SNV Pathogenic 376676 rs1057520006 17:7577117-7577117 17:7673799-7673799
33 TP53 NM_000546.5(TP53):c.472C>T (p.Arg158Cys) SNV Pathogenic 127812 rs587780068 17:7578458-7578458 17:7675140-7675140
34 TP53 NM_000546.5(TP53):c.493C>T (p.Gln165Ter) SNV Pathogenic 182930 rs730882001 17:7578437-7578437 17:7675119-7675119
35 KIT NM_000222.3(KIT):c.1621A>C SNV Pathogenic 41599 rs3822214 4:55593464-55593464 4:54727298-54727298
36 BRAF NM_001374258.1(BRAF):c.1397G>C (p.Arg466Thr) SNV Pathogenic 977765 7:140482858-140482858 7:140783058-140783058
37 STK11 NM_000455.5(STK11):c.1071G>T SNV Pathogenic 412537 rs556651007 19:1223134-1223134 19:1223135-1223135
38 ABL1 NM_005157.6(ABL1):c.764A>T (p.Glu255Val) SNV Pathogenic 376091 rs121913449 9:133738364-133738364 9:130862977-130862977
39 ABL1 NM_005157.6(ABL1):c.1187A>G (p.His396Arg) SNV Pathogenic 376097 rs121913454 9:133750356-133750356 9:130874969-130874969
40 HRAS NM_005343.4(HRAS):c.35G>A (p.Gly12Asp) SNV Pathogenic 12612 rs104894230 11:534288-534288 11:534288-534288
41 HRAS NM_005343.4(HRAS):c.181C>A (p.Gln61Lys) SNV Pathogenic 12601 rs28933406 11:533875-533875 11:533875-533875
42 HRAS NM_005343.4(HRAS):c.182A>T (p.Gln61Leu) SNV Pathogenic 376033 rs121913233 11:533874-533874 11:533874-533874
43 TP53 NM_000546.6(TP53):c.215C>G (p.Pro72Arg) SNV Pathogenic 12351 rs1042522 17:7579472-7579472 17:7676154-7676154
44 TP53 NM_000546.6(TP53):c.455C>T (p.Pro152Leu) SNV Pathogenic 142766 rs587782705 17:7578475-7578475 17:7675157-7675157
45 RB1 NM_000321.3(RB1):c.2039T>C (p.Ile680Thr) SNV Pathogenic 977767 13:49033902-49033902 13:48459766-48459766
46 CDKN2A NM_000077.5(CDKN2A):c.233_234del (p.Leu78fs) Microsatellite Likely pathogenic 977782 9:21971124-21971125 9:21971125-21971126
47 EGFR NM_005228.5(EGFR):c.2235_2237del (p.Glu746del) Deletion Likely pathogenic 977766 7:55242464-55242466 7:55174771-55174773
48 TP53 NM_000546.6(TP53):c.902delC Deletion Likely pathogenic 233908 rs876660726 17:7577036-7577036 17:7673718-7673718
Sources

Expression for Lip and Oral Cavity Cancer

About this section
Search GEO for disease gene expression data for Lip and Oral Cavity Cancer.
Sources

Pathways for Lip and Oral Cavity Cancer

About this section

Pathways related to Lip and Oral Cavity Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 103)
# Super pathways Score Top Affiliating Genes
1
Signaling by GPCR 65
Show member pathways
 14.08 TP53 STK11 PIK3CA KIT HRAS EGFR
2
ERK Signaling 63
Show member pathways
 13.72 TP53 STK11 RB1 KIT HRAS EGFR
3
GPCR Pathway 63
Show member pathways
 13.64 TP53 RB1 KIT HRAS EGFR CDKN2A
4
TGF-Beta Pathway 63
Show member pathways
 13.47 TP53 PIK3CA KIT HRAS EGFR BRAF
5
Developmental Biology 65
Show member pathways
 13.44 PIK3CA KIT HRAS EGFR BRAF ABL1
6
Cytokine Signaling in Immune system 65
Show member pathways
 13.31 TP53 PIK3CA KIT HRAS EGFR BRAF
7
IL-2 Pathway 63
Show member pathways
 13.15 TP53 HRAS EGFR BRAF ABL1
8
TNFR1 Pathway 63
Show member pathways
 13.03 TP53 RB1 PIK3CA HRAS EGFR
9
Phospholipase-C Pathway 63
Show member pathways
 13.03 TP53 KIT HRAS EGFR BRAF
10
Toll-like Receptor Signaling Pathway 36 1
Show member pathways
 13.03 TP53 RB1 PIK3CA HRAS EGFR BRAF
11
PI3K-Akt signaling pathway 36
Show member pathways
 12.93 TP53 STK11 RB1 PIK3CA KIT HRAS
12
Human cytomegalovirus infection 36
Show member pathways
 12.91 TP53 RB1 PIK3CA HRAS EGFR CDKN2A
13
Focal Adhesion 36 1
Show member pathways
 12.88 RB1 PIK3CA HRAS EGFR BRAF
14
Aldosterone synthesis and secretion 36
Show member pathways
 12.88 RB1 KIT HRAS EGFR CDKN2A BRAF
15
Regulation of lipid metabolism Insulin signaling-generic cascades 23
Show member pathways
 12.85 PIK3CA HRAS EGFR BRAF
16
Development Angiotensin activation of ERK 23
Show member pathways
 12.83 PIK3CA KIT HRAS EGFR BRAF
17
NFAT and Cardiac Hypertrophy 63
Show member pathways
 12.82 PIK3CA HRAS EGFR BRAF
18
MAPK signaling pathway 36 1
12.76 TP53 KIT HRAS EGFR BRAF
19
Downstream signaling events of B Cell Receptor (BCR) 65
Show member pathways
 12.73 TP53 PIK3CA KIT HRAS EGFR
20
Ras signaling pathway 36
Show member pathways
 12.72 PIK3CA KIT HRAS EGFR BRAF ABL1
21
Development HGF signaling pathway 23
Show member pathways
 12.71 TP53 PIK3CA HRAS BRAF ABL1
22
Apoptosis Modulation and Signaling 1
Show member pathways
 12.68 TP53 PIK3CA HRAS CDKN2A
23
4-1BB Pathway 63
Show member pathways
 12.66 TP53 RB1 HRAS EGFR BRAF
24
Regulation of actin cytoskeleton 36 1
12.61 PIK3CA HRAS EGFR BRAF
25
ErbB signaling pathway 36 1
Show member pathways
 12.6 TP53 PIK3CA HRAS EGFR BRAF ABL1
26
Immune response IL-23 signaling pathway 23
Show member pathways
 12.57 TP53 PIK3CA HRAS EGFR
27
Glioma 36
Show member pathways
 12.55 TP53 RB1 PIK3CA HRAS EGFR CDKN2A
28
Gastric cancer 36
Show member pathways
 12.53 TP53 RB1 PIK3CA KIT HRAS EGFR
29
VEGF Signaling 66
Show member pathways
 12.51 TP53 PIK3CA HRAS EGFR ABL1
30
AMP-activated Protein Kinase (AMPK) Signaling 1
Show member pathways
 12.49 TP53 STK11 PIK3CA HRAS
31
MicroRNAs in cancer 36
12.49 TP53 PIK3CA HRAS EGFR CDKN2A ABL1
32
Apoptosis Pathway 70
Show member pathways
 12.45 TP53 PIK3CA HRAS EGFR
33
mTOR signaling pathway (KEGG) 36
Show member pathways
 12.44 TP53 STK11 PIK3CA HRAS EGFR BRAF
34
Phospholipase D signaling pathway 36
Show member pathways
 12.41 PIK3CA KIT HRAS EGFR
35
G-protein signaling RAC1 in cellular process 23
Show member pathways
 12.4 PIK3CA KIT HRAS EGFR BRAF
36
DNA Damage Response 1
Show member pathways
 12.39 TP53 RB1 CDKN2A ABL1
37
Cell cycle 36 1
12.37 TP53 RB1 CDKN2A ABL1
38
Development ERBB-family signaling 23
Show member pathways
 12.36 PIK3CA HRAS EGFR BRAF
39
Human T-cell leukemia virus 1 infection 36
12.36 TP53 RB1 PIK3CA HRAS CDKN2A
40
Endometrial cancer 36
Show member pathways
 12.36 TP53 RB1 PIK3CA KIT HRAS EGFR
41
Translation Non-genomic (rapid) action of Androgen Receptor 23
Show member pathways
 12.33 TP53 PIK3CA HRAS EGFR
42
G-protein signaling Ras family GTPases in kinase cascades (scheme) 23
Show member pathways
 12.32 TP53 HRAS EGFR BRAF
43
Proteoglycans in cancer 36
12.32 TP53 PIK3CA HRAS EGFR BRAF
44
Viral carcinogenesis 36
12.31 TP53 RB1 PIK3CA HRAS CDKN2A
45
Signaling by ERBB2 65
Show member pathways
 12.26 PIK3CA HRAS EGFR
46
Immune response IFN alpha/beta signaling pathway 23
Show member pathways
 12.26 TP53 RB1 KIT EGFR ABL1
47
Signaling by FGFR2 65
Show member pathways
 12.24 PIK3CA HRAS BRAF
48
p53 Signaling 63
Show member pathways
 12.22 TP53 RB1 ABL1
49
Axon guidance 36
12.21 PIK3CA HRAS ABL1
50
EGF/EGFR Signaling Pathway 1
12.21 HRAS EGFR BRAF ABL1
Sources

GO Terms for Lip and Oral Cavity Cancer

About this section

Cellular components related to Lip and Oral Cavity Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.28 TP53 STK11 PIK3CA KIT HRAS EGFR

Biological processes related to Lip and Oral Cavity Cancer according to GeneCards Suite gene sharing:

(show all 44)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.03 TP53 RB1 HRAS EGFR CDKN2A ABL1
2 positive regulation of gene expression GO:0010628 9.92 TP53 KIT HRAS CDKN2A BRAF
3 apoptotic process GO:0006915 9.91 TP53 STK11 RB1 HRAS CDKN2A ABL1
4 MAPK cascade GO:0000165 9.89 KIT HRAS EGFR BRAF
5 negative regulation of cell proliferation GO:0008285 9.89 TP53 STK11 RB1 HRAS CDKN2A
6 protein phosphorylation GO:0006468 9.88 STK11 PIK3CA KIT EGFR BRAF ABL1
7 autophagy GO:0006914 9.86 TP53 STK11 ABL1
8 positive regulation of protein kinase B signaling GO:0051897 9.85 PIK3CA KIT EGFR
9 regulation of cell cycle GO:0051726 9.85 TP53 RB1 ABL1
10 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.85 HRAS EGFR BRAF ABL1
11 negative regulation of neuron apoptotic process GO:0043524 9.84 PIK3CA HRAS BRAF
12 regulation of cell proliferation GO:0042127 9.84 TP53 KIT BRAF ABL1
13 response to oxidative stress GO:0006979 9.83 TP53 EGFR ABL1
14 protein autophosphorylation GO:0046777 9.81 STK11 KIT EGFR ABL1
15 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.79 PIK3CA EGFR BRAF
16 liver development GO:0001889 9.78 PIK3CA HRAS EGFR
17 peptidyl-tyrosine phosphorylation GO:0018108 9.78 KIT EGFR BRAF ABL1
18 negative regulation of cell growth GO:0030308 9.76 TP53 STK11 RB1 CDKN2A
19 cellular response to drug GO:0035690 9.75 TP53 EGFR BRAF
20 positive regulation of MAP kinase activity GO:0043406 9.74 KIT HRAS EGFR
21 T cell receptor signaling pathway GO:0050852 9.72 STK11 PIK3CA HRAS BRAF ABL1
22 phosphorylation GO:0016310 9.7 STK11 PIK3CA KIT EGFR CDKN2A BRAF
23 cell aging GO:0007569 9.69 TP53 HRAS
24 vasculature development GO:0001944 9.69 STK11 PIK3CA
25 intrinsic apoptotic signaling pathway by p53 class mediator GO:0072332 9.69 TP53 STK11
26 negative regulation of protein serine/threonine kinase activity GO:0071901 9.68 RB1 ABL1
27 cellular senescence GO:0090398 9.68 HRAS CDKN2A
28 tissue homeostasis GO:0001894 9.67 STK11 RB1
29 positive regulation of actin cytoskeleton reorganization GO:2000251 9.67 HRAS ABL1
30 Ras protein signal transduction GO:0007265 9.67 TP53 RB1 HRAS CDKN2A
31 replicative senescence GO:0090399 9.66 TP53 CDKN2A
32 regulation of T cell differentiation GO:0045580 9.65 BRAF ABL1
33 regulation of cellular senescence GO:2000772 9.65 TP53 ABL1
34 positive regulation of phospholipase C activity GO:0010863 9.64 KIT HRAS
35 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.64 TP53 EGFR
36 tongue development GO:0043586 9.63 KIT EGFR
37 anoikis GO:0043276 9.63 STK11 PIK3CA
38 negative regulation of ubiquitin-protein transferase activity GO:0051444 9.62 CDKN2A ABL1
39 somatic stem cell division GO:0048103 9.62 KIT CDKN2A
40 alpha-beta T cell differentiation GO:0046632 9.6 BRAF ABL1
41 myeloid progenitor cell differentiation GO:0002318 9.58 KIT BRAF
42 epidermal growth factor receptor signaling pathway GO:0007173 9.56 PIK3CA EGFR BRAF ABL1
43 negative regulation of mitotic cell cycle GO:0045930 9.26 TP53 RB1 EGFR ABL1
44 cell cycle arrest GO:0007050 9.1 TP53 STK11 RB1 HRAS CDKN2A ABL1

Molecular functions related to Lip and Oral Cavity Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transferase activity GO:0016740 9.93 STK11 PIK3CA KIT EGFR BRAF ABL1
2 nucleotide binding GO:0000166 9.91 STK11 PIK3CA KIT HRAS EGFR BRAF
3 protein kinase activity GO:0004672 9.72 STK11 KIT EGFR BRAF ABL1
4 ATP binding GO:0005524 9.7 TP53 STK11 PIK3CA KIT EGFR BRAF
5 p53 binding GO:0002039 9.58 TP53 STK11 CDKN2A
6 MAP kinase kinase kinase activity GO:0004709 9.48 EGFR BRAF
7 MDM2/MDM4 family protein binding GO:0097371 9.43 TP53 CDKN2A
8 disordered domain specific binding GO:0097718 9.43 TP53 RB1 CDKN2A
9 protein tyrosine kinase activity GO:0004713 9.26 KIT EGFR BRAF ABL1
10 kinase activity GO:0016301 9.17 STK11 PIK3CA KIT EGFR CDKN2A BRAF
Sources

Sources for Lip and Oral Cavity Cancer

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....